findmyKOL
Clinical trialNCT03030378Active, not recruitingPhase 1Interventional

Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors

SponsorNational Cancer Institute (NCI)Enrollment36Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid Neoplasm
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

27 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of California Davis Comprehensive Cancer Center

    Sacramento, California, United States

  • Ucsf Medical Center-Mount Zion

    San Francisco, California, United States

  • Uchealth University of Colorado Hospital

    Aurora, Colorado, United States

  • Smilow Cancer Center/yale-New Haven Hospital

    New Haven, Connecticut, United States

  • Yale University

    New Haven, Connecticut, United States

  • Uf Health Cancer Institute - Gainesville

    Gainesville, Florida, United States

  • Emory Saint Joseph'S Hospital

    Atlanta, Georgia, United States

  • Emory University Hospital Midtown

    Atlanta, Georgia, United States

  • Emory University Hospital/winship Cancer Institute

    Atlanta, Georgia, United States

  • University of Iowa/holden Comprehensive Cancer Center

    Iowa City, Iowa, United States

  • Johns Hopkins University/sidney Kimmel Cancer Center

    Baltimore, Maryland, United States

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, United States

  • Brigham and Women'S Hospital

    Boston, Massachusetts, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, United States

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts, United States

  • Siteman Cancer Center at Saint Peters Hospital

    City of Saint Peters, Missouri, United States

  • Siteman Cancer Center at West County Hospital

    Creve Coeur, Missouri, United States

  • Siteman Cancer Center at Christian Hospital

    St Louis, Missouri, United States

  • Siteman Cancer Center-South County

    St Louis, Missouri, United States

  • Washington University School of Medicine

    St Louis, Missouri, United States

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey, United States

  • Unc Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina, United States

  • Duke University Medical Center

    Durham, North Carolina, United States

  • Cleveland Clinic Foundation

    Cleveland, Ohio, United States

  • University of Pittsburgh Cancer Institute (upci)

    Pittsburgh, Pennsylvania, United States

  • University of Texas Health Science Center at San Antonio

    San Antonio, Texas, United States

  • Vcu Massey Comprehensive Cancer Center

    Richmond, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 May 2018
Primary completion
1 Dec 2026
Completion
1 Dec 2026
Last update posted
19 May 2026
Registered enrollment
36
Registry id
NCT03030378

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.